☄️This is the first compulsory license for dolutegravir, and this is somewhat strange because dolutegravir is a key drug for the treatment of HIV infection.
🤝🏻It is encouraging to see that there are countries taking action to improve access to treatment for their citizens.
Desde Fundación GEP celebramos la Declaración de interés público para Dolutegravir de
#Colombia, un paso previo para la licencia obligatoria.